Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The market does not anticipate them winning so they shouldn't have a drop when they lose.
Thank you
Yes it is. Cardiology Today circulation is 53,432. That one article takes the place of many drug reps.
Cardiology Today
@CardiologyToday
·
1h
Our February issue is now online! Read about recent developments in diagnosis and treatment of cardiac #amyloidosis, the success of #Vascepa despite failure of other #omega3 fatty acids in #CVD prevention and much more. https://healio.com/cardiology/news/print/cardiology-today
These types of articles can take the place of many sales reps. V. is easy to prescribe.
The other alternative is to get access to a Bloomberg Terminal.
They are not creating any of that from scratch. That did that in 2012.
Yes, very good chance of Amarin victory. Can't say 100% chance though.
I asked my daughter who is a patent attorney to read through it. She called me later in the day and she said that the generics are still grasping at straws. She told me she couldn't tell me 100% how the judge would rule because there is always that element of risk.
It looks to me like the defendants tried to include arguments for why they have grounds to appeal since they don't believe they will win.
Keep in mind, Vascepa is now included in AACE, AHA, ESC, NLC, and Diabetes Association guidelines. Any physician using their guidelines is going to run into Vascepa and need to consider it.
With continued sales growth throughout 2020, other institutions will be buying in as some did in 4th Qtr. They will be a different type of investor.
I agree with much of that but if you have readings above 150 before being on Vascepa they should allow you to continue on it.
Why would you say the healthcare system is broken? Part of the reason Prior auths are put into place is so that only the people who should getting the drug are getting the drug. It is creating a little bump in our road to blockbuster status but it will happen soon enough. I do think everyone should be on V. but we need to work through the proper system to get everyone on it. Trigs > 150 on the label is great and with the diabetes association and AACE going with 135, there is a way for many more patients to get on it.
Congratulations on your big fat clear veins.
If Amarin only files Reduce-it Patents to Europe will they have 20 years patent life? My understanding is that they are not going to go after the first indication in Europe. From the documents that HDG posted this morning it doesn't look like the Reduce-it patents overlap with the earlier patents.
Insurance companies and pharmacy benefit administrators when faced with a drug that they think is going to blow their budget out of the water put in prior authorization. It is part of their cost saving strategies. A soon to be blockbuster needs to be managed. The label is broad and insurance companies know it. There will be plenty of on label patients who will be prescribed this drug. It is the only drug for the label and that will get worked out in time. I think that is why Amarin gave very conservative guidance but they know they will beat it as the year goes on. We are going to need a little patience here but things are a changing.
Thank you for posting.
I think there are a fair amount of State Medicaid plans across the country that have Generic Lovaza on a prior auth and they have to have failed fibrates and /or niacin. I think that is where some of disconnect lies.
There are 36 different BCBS plans across the country and they use different pharmacy benefits administrators. We really need to be more specific here.
You might say that some plans are covering it but all plans need to cover it and it needs to be at a reasonable price as this medicine should be an essential health benefit.
CMS (Center for Medicare and Medicaid Services) pays the individual commercial plans to administer the drugs that CMS thinks should be covered. We need to get CMS to require the plans to cover this drug that is the only drug for this indication. It is a federal program and a federal agency. Please contact your Congressman, CMS and AARP to ask for help with this.
AMRN is not in many indexes. It does not necessarily trade with the market. When people look for opportunity, they will be looking at Amarin whether it is today, this month or later in the year.
I would not take anything that guy says seriously.
Latest short interest drop of almost 5 Million.
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
01/31/2020 41220757 6022265 6.844727
01/15/2020 46033996 9079690 5.069996
12/31/2019 44564427 12665251 3.518637
12/13/2019 47417478 6319096 7.503839
11/29/2019 45868031 13036251 3.518499
11/15/2019 48386316 16603924 2.914149
Based on what you posted, BB's have not updated their forms yet. That is showing 9/30 numbers.
That sounds like your trade off. Higher out of pocket for Vascepa and potentially anything else you may need this year. Hopefully you have a good healthy year. Health insurance is such a sham in the U.S.
It looks like you might have been better off picking the other plan.
It looks like it is $125 for three months total, if you use the 3 month mail order. That is before you use the Amarin discount.
So this is a low end Medicare part D plan? If so, as mentioned before you (and others) need to talk to your Congressman, AARP and CMS in order to get CMS to start paying the Medicare Part D plans for this drug. It is not going to happen overnight.
Which formulary is it?
I would not call February radio silence. We will have Canadian launch, we have quarterly earnings release and we have these upcoming documents including closing arguments from the trial. Once closing arguments are filed, there will be analyst commentary.
"Case 2:16-cv-02525-MMD-NJK Document 358 Filed 01/29/20 Page 3 of 3
includes the exhibit number, relevant page of the exhibit, and a statement as to why there is a compelling interest to seal that portion of the exhibit by 2/11/2020. Defendants have until 2/12/2020 to respond to Plaintiff’s list of redactions.
The Court will allow counsel to file amended proposed findings of fact, conclusions of law that cite to the transcripts. The amended proposed findings of fact, conclusions of law are due by 2/14/2020. Closing briefs are due by 2/28/2020. Counsel are to limit their closing briefs to 30 pages. Counsel are to email Word versions of the findings "
No, it wasn't my first post. I first bought Amarin 4/24/2012. I've been around for years. I got locked out of my previous account and could never figure out how to get back in it. I did not post here for years or own any shares for some of that time. I bought back in before reduce it results. My house and cars are paid off. We went to Portugal in the fall and Hawaii in January. Life is good. I have paid some taxes in 2018 and 2019 from sales of AMRN. I understand finance and I don't need a messiah. I have been around biotechs long enough to know that this is a flush and they are trying to flush you out. I followed John Cappelo on twitter to keep up with the science over the years. I make my own decisions. I currently own 67, 852 shares and have a nice gain on them.
So anyway, I probably do not know JL or some of the other posters like many of you do because I haven't felt the need to savor every one of their posts.
JL sold some shares because of his personal financial position. Just because it was right for him to do so at this time does not mean that it is right for someone else. If you have been to a financial advisor you would know that everyone has different risks that they are willing to take. Some of the risk is based on age and some is based on debt and some is based on other investments and some is based on how safe you want to be.
As an aside, As far as HDG, (no offense to him) if he was a patent attorney who worked with pharmaceutical companies and he spoke English as his first language, I might consider his position relevant. Otherwise, I think most of what he has written is just words put together into posts.
They are not independent. The market cap would not be where it is today if anyone truly thought that there was a chance that the trial outcome was not in Amarin's favor.
After Reduce-It, I assume your position was a larger portion of your portfolio than is probably appropriate at your age. I get that. It probably should not be more than 10% of your assets. Everyone needs to weight their position in Amarin after such large gains and see if it is appropriate . If it is money that you can gamble and feel the risk is appropriate, then that is great.
I had a dividend account that gives me enough dividends to live on. Amarin is in a second account with what was "play money" and has become serious money. At your age, I would not want to have such a large stake at risk, dependent on this trial. I have been around long enough to see this game played over and over. Institutions are still in Amarin and the market cap still reflects a belief that Amarin will prevail. I'm willing to keep my bet in place.
One drug companies do not have a 6.4B market cap if the outcome was in doubt.
"Branded direct to consumer (DTC) promotion to heighten mid’20 after OPDP approval"
February 2020 investor presentation says it is to heighten mid'20. That doesn't mean it will not ramp up before that.
Gwen Fisher, no longer at Amarin -
From her LinkedIn Page -
Vice President
Company Name Amarin Corporation Full-time
Dates Employed May 2019 – Jan 2020
Employment Duration9 mos
Location Greater New York City Area
Responsible for establishing the corporate communications function, inclusive of internal and external communications, at Amarin. Initial focus on advancing and implementing an integrated, progressive corporate communications strategy designed to educate key stakeholders about the company and its lead cardiovascular product, Vascepa. Served as strategic advisor to executive team and led communications through pivotal milestones, including FDA advisory committee meeting; third-party drug pricing watch dog review; key medical meetings; and FDA approval of expanded indication for lead product.
There isn't an analyst out there that thinks the court is going to rule against AMRN.
At his age and at this point in time, it is right for him. Good for him. Not right for everyone though. Hopefully he know he needs to pay some interim taxes though so he doesn't get penalties.